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Purpose: Bardet-Biedl syndrome (BBS, OMIM 209900) is a rare multi-organ disorder in which BBS patients manifest
a variable phenotype that includes retinal dystrophy, polydactyly, mental delay, obesity, and also reproductive tract and
renal abnormalities. Mutations in 14 genes (BBS1–BBS14) are found in 70% of the patients, indicating that additional
mutations in known and new BBS genes remain to be identified. Therefore, the molecular diagnosis of this complex
disorder is a challenging task.
Methods: In this study we show the use of the genome-wide homozygosity mapping strategy in the mutation detection
of nine Caucasian BBS families, eight of them consanguineous and one from the same geographic area with no proven
consanguinity.
Results: We identified the disease-causing mutation in six of the families studied, five of which had novel sequence
variants in BBS3, BBS6, and BBS12. This is the first null mutation reported in BBS3. Furthermore, this approach defined
homozygous candidate regions that could harbor potential candidate genes for BBS in three of the families.
Conclusions: These findings further underline the importance of homozygosity mapping as a useful technology for
diagnosis in small consanguineous families with a complex disease like BBS.
Bardet-Biedl  syndrome  (BBS,  OMIM  209900)  is  a
pleiotropic  human  genetic  disorder  that  has  as  primary
phenotypic features early-onset retinitis pigmentosa, obesity,
dystrophic  extremities,  and  polydactyly  together  with
reproductive  tract  and  renal  abnormalities  and  a  variable
degree of cognitive impairment [1].
BBS is rare in the general population, with prevalence
rates in North America and Europe ranging from 1:140,000
to 1:160,000 live births [2,3]. However, a higher incidence has
recently been reported in certain isolated populations, such as
those in Newfoundland, Kuwait, and the Faroe Islands [4–6].
BBS has a heterogeneous genetic nature with at least 14
genes  (BBS1–BBS14)  identified  to  date  [7,8];  this  shows
considerable interfamilial and intrafamilial variation in the
phenotype  [7].  BBS  has  been  defined  as  an  autosomal
disorder,  but  some  families  harbor  a  model  of  complex
inheritance where additional mutations in other genes modify
the phenotype [7,8]. Mutation screening of the known BBS
genes  has  resulted  in  the  identification  of  the  causative
mutations  in  approximately  70%  of  the  BBS  families,
indicating that additional BBS genes remain to be identified
[9].
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BBS  is  a  difficult  disease  upon  which  to  perform
molecular diagnostic studies. It is tedious and time consuming
to search for mutations in each of the 14 genes described as
some of them have been implicated in only a few cases and
several  genes  present  large  coding  regions  in  which  it  is
necessary to search for mutations.
The genome-wide homozygosity mapping approach has
been  useful  for  molecular  diagnosis  studies  of  complex
diseases, for the search for new mutations in known genes, as
well  as  for  identifying  new  disease  genes  [10–13].  This
technology is based on the assumption that patients with a
recessive disease and born from a consanguineous union are
likely to be homozygous for the disease-causing mutation and
for polymorphisms in the region surrounding this mutation
[14].
Therefore, the aim of this study was to use genome-wide
homozygosity  mapping  to  diagnose  BBS  patients  from
consanguineous  families.  Identifying  homozygous
chromosomal regions in these families allowed us to search
for mutations in the known BBS genes and to find new BBS
loci within candidate regions.
METHODS
Nine Caucasian families from Spain with one or more affects
of BBS, eight of them consanguineous and one (M250) from
the same geographic area with no proven consanguinity, were
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137selected from our pool of Spanish BBS patients. The pedigrees
of the families and the gender of the BBS affects are shown
in Figure 1. The recruitment of patients and relatives was
performed  through  the  Retinal  Dystrophy  Investigation
Spanish Network (EsRetNet). Informed consent was obtained
from all patients and relatives after the nature and possible
consequences of the study had been explained.
Clinical diagnosis was based on the criteria described by
Beales et al. [1], where the presence of at least three main and
two minor phenotypic characteristics are necessary. Clinical
information of the BBS patients is summarized in Table 1. No
detailed clinical data were available for patients from the B64
family, as the clinical history was lost.
DNA extraction from 10 ml of whole blood samples was
performed by a salting-out procedure described by Miller et
al. [15].
In all BBS patients, except those from the M496 family,
as  the  DNAs  were  degraded,  the  presence  of  previously
described mutations in the BBS1–BBS10 genes were excluded
by using a genotyping microarray based on arrayed primer
extension (APEX) technology (Asper Ophthalmics, Tartu,
Estonia).
DNA  from  the  BBS  patients  was  genotyped  on  an
Affymetrix  GeneChip  Human  Mapping  50K  (Affymetrix,
Santa Clara, CA) to detect homozygous regions, previously
described by Nishimura et al. [13]. When a known BBS gene
was localized in a homozygous region of a given family, the
coding sequence and the consensus splice sites of that gene
were sequenced. To exclude some of the homozygous regions
detected in family RP329, we also genotyped the healthy
siblings of this family with the same methodology, and this
gave us information about the homozygous regions shared
only by the BBS patients in this family.
To determine if novel BBS gene variants (p.G250R and
p.L454P  [BBS6]  and  p.P108L  [BBS12])  were  present  in
control samples, we sequenced 100 chromosomes of a control
population  provided  by  the  Complejo  Hospitalario
Universitario de Vigo (Vigo, Spain). The BBS12 p.G540D
mutation  was  tested  by  a  BsgI  restriction  assay.  In  the
restriction assay a 665 bp amplicon was cleaved into three
fragments of 434, 129, and 102 bp, respectively, when the
normal  allele  is  present;  whereas  the  p.G540D  mutation
abolishes one BsgI site producing two fragments of 434 bp
and 231 bp, respectively.
To  evaluate  the  potential  pathogenic  effect  of  the
missense mutations, we used a homolog protein alignment
program. Furthermore, we used a splice site scoring program
to test for DNA variants effect on splicing.
RESULTS
The  homozygosity  regions  detected  in  seven  of  the  nine
families (M446, M79, B17, M250, B64, RP1011, and M496)
Figure 1. Pedigrees of the Bardet-Biedl syndrome families studied showing the segregation of the mutations found. Each pedigree were named
with the family code and the mutated BBS gene. aFamilies with mutations detected, bfamilies without mutations detected. *Novel mutations,
**mutation reported by Stoetzel et al. [16] wt denotes wild type.
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139included known BBS genes. The sequencing of these BBS
genes revealed sequence variants in six families that were
always detected as homozygous. In five families the detected
sequence variants were novel (Figure 1).
In the M446 family, we identified a novel homozygous
nonsense mutation p.G2X (c.4G>T) in BBS3. In families M79
and B17, two novel BBS6 missense mutations were found,
p.G250R  (c.748G>A)  and  p.L454P  (c.1361T>C),
respectively.  Finally,  BBS12  missense  mutations  in
homozygous state were detected in families B64, p.P108L (c.
3232C>T) and RP1011, p.G540D (c.1620 G>A). Another
BBS12 mutation, a previously described frameshift mutation
[16],  p.F372fsX373  (c.1114delTT),  was  detected  in  both
patients from family M250. In each family all of the mutations
segregated  with  the  disease  (Figure  1),  consistent  with  a
pattern  of  autosomal  recessive  inheritance.  Moreover,  the
mutations detected were not found in 100 ethnically matched
control chromosomes. Determination of mutation segregation
in families B17 and B64 was not possible.
The  application  of  the  splice  site  scoring  programs
showed that none of the changes detected seemed to modify
the splice site or create new splice sites. Protein sequence
alignment showed that all of the novel missense mutations are
localized within conserved regions (Figure 2).
For  family  M496,  homozygous  regions  included  the
BBS3 and BBS6 genes, but the sequencing of the exon and
intronic boundaries of those genes did not reveal candidate
pathogenic variants. However, for the M496, RP329, and
M523 families, we were able to detect several homozygous
regions along the genome (Table 2). In the case of family
RP329, the candidate homozygous regions were redefined by
the genotyping of the unaffected siblings.
DISCUSSION
We report the utility of high-density technologies, such as
genome-wide  Single  Nucleotide  Polymorphism  (SNP)
genotyping,  in  identifying  disease-causing  mutations  in
recessive  complex  diseases,  such  as  the  Bardet-Biedl
syndrome. In this study, the homozygosity mapping of eight
consanguineous  families  and  one  family  from  a  small
geographic area allowed us to identify in six families six
sequence variants in known BBS genes.
Of the BBS gene sequence changes detected, one was
previously  described  and  five  were  novel  variants  (one
nonsense mutation and four missense mutations). As evidence
of the pathogenicity of the novel missense variants, (i) all
mutations were found to localize within conserved regions of
the genes, (ii) the mutations segregated with the disease, (iii)
the mutations were absent in 100 control chromosomes, and
(iv)  the  mutations  were  not  found  in  the  database  SNP
(dbSNP) database.
The BBS3 (also known as ADP-ribosylation factor-like
protein 6 [ARL6]) nonsense mutation (p.G2X) seems to be a
Figure 2. Sequence alignment of BBS6
protein and BBS12 protein of several
species, showing the conservation of the
amino acid implicated in the missense
mutations.  A:  BBS6  mutations
(p.G250R  and  p.L454P);  B:  BBS12
mutations (p.P108L and p.G540D).
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140null  mutation  because,  in  theory,  it  does  not  allow  the
formation of the BBS3 protein. Although this mutation may
be disease-causing in the M446 family, its consequences do
not seem to be any worse than in the other BBS families
because there are no major phenotypic differences among the
families studied (Table 1). However within the two affected
brothers with the same mutation, the phenotype is clearly
different.  For  the  younger  brother  the  progression  of  the
disease has been quite slow, with a reduction of the visual field
at the age of 18 and a diminished visual acuity at 22 and no
polydactyly. For the proband in this family, major clinical
characteristics  have  been  observed:  polydactyly,  obesity,
retinitis pigmentosa, dysmorphic facial features, and hearing
loss. It was not possible to obtain an electroretinogram (ERG)
from the proband. None of the two brothers shows mental
delay. ARL6 is a member of a subgroup of the ARF family
adenosine diphosphate ribosylation factor (ADP-ribosylation
factor) that is involved in diverse cellular functions, including
the regulation of intracellular traffic. It is a cytosolic protein
with the highest levels of mRNA being present in the brain
and kidney [17]. The ARL6 mRNA expression pattern during
early mouse embryonic development is on the ventral layer
node, which is distinguished by the presence of a single,
motile,  central  cilium  [18].  Functional  analyses  of  this
mutation are needed to elucidate the role of this protein in the
development of the clinical characteristics of BBS.
For families M79 and B17, the mutation was detected in
the BBS6 gene. The patients from the M79 family and the B17
family are homozygous for the p.G250R mutation and the
p.L454P mutation, respectively. Both changes affect the Pfam
domain of the protein by modifying the ATPase activity and
the  protein-binding  site.  For  the  p.G250R  mutation,  the
neutral glycine with a simple lateral chain changed to the basic
arginine with a longer lateral chain. For the p.L454P mutation,
although the apolar characteristic of the amino acid did not
change, the lateral chain of proline has special characteristics
that could influence protein configuration.
The clinical ocular phenotype of patient M79 showed an
onset of night blindness at the age of 3, with diminished visual
acuity  and  a  diminished  peripheral  visual  field  and  an
abolished ERG at the age of 12. Clinical characteristics typical
of BBS are present, except for renal affectation. For patient
B17, a typical visual phenotype with night blindness and an
abolished  ERG  was  observed,  together  with  other  typical
clinical characteristics, such as renal insufficiency and high
arterial hypertension.
For families M250, B64, and RP1011, mutations in the
BBS12 gene have been detected (p.F372fsX373, p.P108L, and
G540D, respectively). For the two affected brothers of family
M250, differences in the phenotype have been reported. One
brother shows a more severe phenotype, with polydactyly in
all  extremities,  photophobia,  and  myopia.  The  retinitis
pigmentosa (RP) debuted with night blindness at the age of
15 with a decreased visual acuity at the age of 20. The other
brother developed night blindness during infancy, a reduced
visual acuity at the age of 20 and was born with polydactyly
in the left foot. Both brothers had hypogonadism. For family
RP1011, the age of onset of the RP is in the first decade of
life, showing an aggressive progression as well as polydactyly
in both hands and feet, obesity, and psychomotor delay.
The  previously  discussed  phenotypic  differences
between affected siblings carrying the same BBS mutation
could be explained by the presence of a third mutation. This
TABLE 2. HOMOZYGOUS REGIONS IDENTIFIED BY SNP GENOTYPING IN THE BBS FAMILIES WITHOUT MUTATION DETECTED.
Family Chromosomal region Interval size (Mb)
M496 3p12.3-q13.13* 32.46
9p22.2-p13.3 18.69
13p13-q12.13 25.06
13q13.3-q21.31 25.72
16q21-q24.3 25.72
20p12.3-q13.12** 36.08
M523 1q23.3-q31.3 34.05
6p25.3-p24.1 11.91
7p14.2-q11.22 35.41
9p24.1-p22.3 9.72
RP329 1p21.3-p13.3 13.70
1q32.3-q41 8.61
15q11.2-q22.31 45.66
18q12.3-q21.2 6.96
* Homozygous region including BBS3 gene. ** Homozygous region including BBS6 gene.
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141third mutation could have a modifying effect modulating the
expression of the disease phenotype [19].
The  sequencing  analysis  performed  to  exclude  the
implication of known BBS genes did not allow us to rule out
the presence of mutations in introns or promoter regions or to
rule out small deletions. However, the use of high-density
SNP genotyping for homozygosity mapping seems to be a
good  screening  strategy  in  consanguineous  families  and
families from a small geographic area to efficiently focus on
mutation detection.
Furthermore,  this  approach  defines  homozygous
candidate regions that could harbor potential candidate genes
for BBS. In the families that did not harbor a mutation in
known BBS genes, the candidate regions did not overlap. This
suggests that the disease in each family might be caused by
different genes. Nevertheless, the number of families included
in this study was small, so the candidate regions identified
were large and numerous and will thus include many false
positives  [20].  The  delimitation  of  these  regions  using
unaffected siblings was limited; it was only possible in one
BBS family (RP329). Therefore, additional studies, such as in
silico  analyses  or  higher  resolution  SNP  analysis,  are
necessary to refine such regions.
This  finding  further  underlines  the  importance  of
homozygosity mapping as a tool for identifying genes and
mutations  involved  in  recessively  inherited  diseases.  This
strategy has been performed in BBS consanguineous families
to detect new genes, such as BBS9 [13], BBS11 [11], and
BBS12  [16];  in  other  retinal  pathologies,  such  as  Leber
congenital amaurosis, this strategy allowed the identification
of novel mutations in the LCA5 gene [21].
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